Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-10-2014 | Retinal Disorders

Bimonthly injections of ranibizumab for age-related macular degeneration

Authors: Tomoko Sawada, Masashi Kakinoki, Xiying Wang, Hajime Kawamura, Yoshitsugu Saishin, Masahito Ohji

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 10/2014

Abstract

Purpose

To evaluate the efficacy of bimonthly intravitreal injections of ranibizumab for age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) in a pilot study.

Methods

This study was a prospective, interventional case series. Thirty eyes of 30 patients received prospectively at least three bimonthly intravitreal injections of ranibizumab (0.5 mg/0.05 ml) without loading doses. The best-corrected visual acuity (BCVA) and the central retinal subfield thickness (CRST) were measured before and monthly after the injections.

Results

Twenty-eight patients received the three planned injections; one patient refused the third injection, one patient did not receive the third injection because blood pressure was raised, and one patient received a rescue injection at month 5 because of increased retinal thickness. The mean logarithm of the minimum angle of resolution (logMAR) BCVA was 0.44 ± 0.37 before treatment and significantly improved to 0.25 ± 0.34 at month 6 (p < 0.001). The mean CRST was 335 ± 85.9 μm before treatment and decreased significantly to 261 ± 78.1 μm at month 6 (p < 0.001). Nine of 30 patients received six planned injections for 12 months. The mean logMAR BCVA was 0.38 ± 0.39 before treatment and significantly improved to 0.18 ± 0.33 at month 12 (p = 0.005). The mean CRST was 360 ± 110.8 μm before treatment and decreased significantly to 249 ± 57.0 μm at month 12 (p = 0.025).

Conclusions

Bimonthly injections of ranibizumab may be effective for treating AMD and PCV.

Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82:844–851PubMedPubMedCentral

Kawasaki R, Wang JJ, Ji G, Taylor B, Oizumi T, Daimon M, Kato T, Kawata S, Kayama T, Tano Y, Mitchell P, Yamashita H, Wong TY (2008) Prevalence and risk factors for age-related macular degeneration in an adult Japanese population. The Funagata Study. Ophthalmology 115:1376–1381PubMedCrossRef

Mitchell P, Smith W, Attebo K, Wang JJ (1995) Prevalence of age-related maculopathy in Australia: The Blue Mountains Eye Study. Ophthalmology 102:1450–1460PubMedCrossRef

Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:12–22CrossRef

Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR (1996) Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37:855–868PubMed

Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW (1996) Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 122:393–403PubMedCrossRef

Kvanta A, Algvere PV, Berglin L, Seregard S (1996) Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37:1929–1934PubMed

Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PTVM (1997) Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 81:154–162PubMedCrossRefPubMedCentral

Otani A, Takagi H, Oh H, Koyama S, Ogura Y, Matumura M, Honda Y (2002) Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res 64:162–169PubMedCrossRef

10.

Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, Nguyen L, Foidart JM, Noël A, Munaut C (2003) Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3186–3193PubMedCrossRef

11.

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431PubMedCrossRef

12.

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444PubMedCrossRef

13.

Tano Y, Ohji M, EXTEND-I Study Group (2010) EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmologoca 88:309–316CrossRef

14.

Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N, PIER Study Group (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:239–248PubMedCrossRef

15.

Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A, EXCITE Study Group (2011) Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 118:831–839PubMedCrossRef

16.

Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG (2009) A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116:1731–1739PubMedCrossRef

17.

Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G, SUSTAIN Study Group (2011) Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 118:663–671PubMedCrossRef

18.

Larsen ML, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, Pilz S, Weisberger A, Study Group MONTBLANC (2012) Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration. Twelve-month MONT BLANC study results. Ophthalmology 119:992–1000PubMedCrossRef

19.

The CATT Research Group (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. Br J Ophthalmol 364:1897–1908

20.

Busbee BG, Ho A, Brown DM, Heier JS, Suner IJ, Li Z, Rubio RG, Lai P, HARBOR Study Group (2013) Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 120:1046–1056PubMedCrossRef

21.

Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegrand SJ, Yancopoulos GD, Rudge JS (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393–11398PubMedCrossRefPubMedCentral

22.

Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U, VIEW 1 and VIEW 2 Study Groups (2012) Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548PubMedCrossRef

23.

Cohen SY, Maloberti B, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C, Grenet T, Quentel G (2014) Bimonthly ranibizumab for neovascular age-related macular degeneration. Ophthalmologica 231:80–85PubMedCrossRef

24.

US Food and Drug Administration (2011) FDA labeling information - Eylea. FDA website [online], http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125387lbl.pdf

25.

Droege KM, Muether PS, Hermann MM, Caramoy A, Viebahn U, Kirchhof B, Fauser S (2013) Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol 251:1281–1284PubMedCrossRef

26.

Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Queré S, Schneider V, LUMIERE Study Group (2013) Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice. The LUMIERE Study. Retina 33:474–481PubMedCrossRef

27.

Muether PS, Hermann MM, Viebahn U, Kirchhof B, Fauser S (2012) Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab. Ophthalmology 119:2082–2086PubMedCrossRef

28.

Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V (2005) Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46:726–733PubMedCrossRef

29.

Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab. Ophthalmology 114:2179–2182PubMedCrossRef

30.

Christoforidis JB, Williams MM, Kothandaraman S, Kumar K, Epitropoulos FJ, Knopp MV (2012) Pharmacokinetics properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT. Curr Eye Res 37:1171–1174PubMedCrossRef

31.

Wang X, Sawada T, Kakinoki M, Miyake T, Kawamura H, Saishin Y, Liu P, Ohji M (2013) Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 07 November 2013. [Epub ahead of print]

Title: Bimonthly injections of ranibizumab for age-related macular degeneration
Authors: Tomoko Sawada
Masashi Kakinoki
Xiying Wang
Hajime Kawamura
Yoshitsugu Saishin
Masahito Ohji
Publication date: 01-10-2014
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 10/2014
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-014-2612-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Bimonthly injections of ranibizumab for age-related macular degeneration

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2014

Reply to rebuttal: early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (results of a proof of concept study)

Spectral-domain optical coherence tomography findings in pediatric tilted disc syndrome

Pocket Guide to Ocular Oncology and Pathology, Grossniklaus H E, Bergstrom C, Baker Hubbard G, Wells J R, Singh A. ISBN: 978-3-642-28911-8 Springer

Increased serum VEGF and b-FGF in Graves’ ophthalmopathy

Photoreceptor inner and outer segment layer thickness in multiple evanescent white dot syndrome

A new model for in vitro testing of vitreous substitute candidates